Native Pet Bolsters Operations and R&D With Executive Hires

Native Pet, the St. Louis-based clean-label supplement maker that basically wrote the playbook on DTC pet branding, announced three senior appointments on April 13. The hires signal a pivot toward scaling manufacturing, accelerating product innovation, and deepening retail partnerships as the company pushes beyond 13,000 store locations nationwide.

What Happened

Native Pet tapped David McCoy as VP of Supply Chain, Bradley Brown as Director of R&D, and Beth Galli as Director of Pet Specialty. McCoy brings supply chain and pet food sourcing expertise from stints at Instinct, Solid Gold, and Purina. Brown joins from Purina and Whitebridge Pet Brands, where he worked on clinically backed product formulations. Galli will oversee relationships within the pet specialty retail channel.

The appointments arrive less than three years after the company's Series B funding round, an $11 million raise led by CAVU Consumer Partners in August 2023. That round followed a $6 million Series A from CAVU Venture Partners in March 2022, with backing from Mars Companion Fund and Selva Ventures. Total disclosed funding sits at approximately $17 million, though some sources indicate the actual figure may exceed $25 million.

If you know Native Pet, you know the brand. They've been one of the standout players in the supplement space, known for clean-label positioning and branding that resonated early and at scale. The company is stocked at PetSmart, Pet Supplies Plus, and independent specialty retailers. The pet supplement market itself is among the fastest-growing segments within pet care, outpacing broader pet food growth rates.

Why It Matters

Native Pet has always been a branding-first story. These hires suggest the company is ready to back that brand up with operational muscle.

1. Supply chain and sourcing have become competitive moats. Pet supplement manufacturers face real ingredient sourcing complexity: raw material availability, quality consistency, regulatory compliance. McCoy's hire suggests Native Pet has identified this as the next bottleneck. As the category heats up and competitors multiply, reliable, affordable sourcing becomes a margin driver. If they can secure exclusive ingredient partnerships or build more efficient sourcing than rivals, it extends clean-label positioning beyond marketing into actual cost advantage.

2. R&D credibility determines brand hierarchy. Brown's background at Purina and Whitebridge matters because those companies publish third-party research on product efficacy. Native Pet has marketed the clean-label story effectively, but hasn't yet built a reputation for clinically proven formulations the way Purina or Hill's have. Bringing in Brown signals an intent to move from ingredient storytelling to efficacy claims backed by trials and published data. That shift could justify premium pricing and unlock veterinary channel sales, a higher-margin distribution layer than retail.

3. The specialty channel is where supplement margins live. Mass retail (PetSmart, Pet Supplies Plus) provides volume. Specialty shops and feed stores provide margin and consumer loyalty. Galli's hire indicates the company sees category growth concentrating in specialty channels where consumers spend more per transaction and stick longer with trusted brands. That's particularly important as major retailers consolidate and reduce shelf space for low-velocity SKUs.

Taken together, these hires reframe Native Pet's next chapter. The company isn't just scaling distribution; it's investing in becoming a more defensible product and supply company. Supplement categories eventually consolidate, and winners tend to be the brands that combine clean positioning with actual clinical differentiation and efficient sourcing.

What to Watch

Whether Native Pet's R&D push yields published clinical data in the next 18 months. Efficacy claims are the unlock for veterinary-channel distribution, which could double margins compared to retail. Brown's Purina background suggests he knows how to navigate regulatory pathways and third-party research, but execution risk remains.

Watch also whether the supply chain investments translate to margin expansion or just reinvestment in growth. If Native Pet can grow at 20-30% annually while protecting gross margins above 60%, the Series C story gets a lot more interesting. If margins compress despite scale, the company faces the same commodity pricing dynamics that plague many supplement makers.

Finally, track whether specialty retail partnerships accelerate. Galli's hire is fundamentally a bet that specialty, not mass retail, will drive the next phase of growth. If Native Pet lands meaningful shelf space in feed stores, pet specialty boutiques, and vet clinics over the next 12 months, the strategy is working. If distribution stays concentrated in PetSmart and online, the company remains vulnerable to retailer bargaining power.

Source: Native Pet Enters Next Phase of Growth with Key Leadership Additions via PR Newswire